Drug Trial Radar · NCT02366546
Investigator Initiated Phase 1 Study of TBI-1301
Last checked: Nov 20, 2026Latest source record: Oct 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
9
Actual
Start
Mar 2015
Primary completion
Sep 2018
Sponsor
- Lead sponsor
- Mie UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Takara Bio Inc.; Shionogi; Fiverings Co., Ltd.; Statcom Co. Ltd.
- First posted
- Feb 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
Conditions
- Solid Tumors
Interventions
TBI-1301Drug
TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
CyclophosphamideDrug
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
FludarabineDrug
Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and grade of adverse events (CTCAE)Time frame: 4 weeks
- Appearance of replication competent retrovirus by PCRTime frame: 4 weeks
- Appearance of clonality by LAM-PCRTime frame: 4 weeks
- Kinetics of TBI-1301 in blood by realtime-PCRTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mie University Hospital
Tsu, Mie-ken, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.